Johnson & Johnson to Exit Kenvue in debt-for-equity deal
Seeking Alpha News (Mon, 13-May 7:34 AM ET)
Johnson & Johnson to exit Kenvue in debt-for-equity deal
Seeking Alpha News (Mon, 13-May 7:34 AM ET)
Kenvue Announces Launch of Secondary Offering
Business Wire (Mon, 13-May 6:46 AM ET)
Business Wire (Thu, 9-May 3:29 PM ET)
Hold Rating on Johnson & Johnson Amid Varipulse PFA Catheter Recall and Approval Uncertainties
TipRanks (Thu, 9-May 6:47 AM ET)
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Business Wire (Wed, 8-May 4:30 PM ET)
The S&P 500 has fallen from its five-month positive performance - HSBC Global
Seeking Alpha News (Wed, 8-May 12:15 PM ET)
AstraZeneca is withdrawing COVID shot worldwide due to vaccine glut
Seeking Alpha News (Wed, 8-May 7:06 AM ET)
TipRanks (Wed, 8-May 12:00 AM ET)
Shockwave Medical Reports First Quarter 2024 Financial Results
Globe Newswire (Mon, 6-May 4:05 PM ET)
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.
As of May 13, 2024, JNJ stock price climbed to $150.87 with 1,293,782 million shares trading.
JNJ has a beta of 0.47, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.12 to the broad based SPY ETF.
JNJ has a market cap of $363.30 billion. This is considered a Mega Cap stock.
Last quarter Johnson & Johnson reported $21 billion in Revenue and $2.71 earnings per share. This fell short of revenue expectation by $-27 million and exceeded earnings estimates by $.07.
In the last 3 years, JNJ stock traded as high as $186.69 and as low as $143.13.
The top ETF exchange traded funds that JNJ belongs to (by Net Assets): RAYD, VTI, VOO, SPY, IVV.
JNJ has underperformed the market in the last year with a return of -3.7%, while the SPY ETF gained +27.9%. In the last 3 month period, JNJ fell short of the market, returning -3.0%, while SPY returned +4.4%. However, in the most recent 2 weeks JNJ has outperformed the stock market by returning +3.2%, while SPY returned +2.6%.
JNJ support price is $148.32 and resistance is $151.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ stock will trade within this expected range on the day.